Faes Farma, S.A.

MCE FAE.MC

Faes Farma, S.A. Free Cash Flow Yield on January 14, 2025: -0.12%

Faes Farma, S.A. Free Cash Flow Yield is -0.12% on January 14, 2025, a 0.79% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Faes Farma, S.A. 52-week high Free Cash Flow Yield is -0.10% on September 27, 2024, which is 16.80% above the current Free Cash Flow Yield.
  • Faes Farma, S.A. 52-week low Free Cash Flow Yield is -0.14% on March 14, 2024, which is -8.80% below the current Free Cash Flow Yield.
  • Faes Farma, S.A. average Free Cash Flow Yield for the last 52 weeks is -0.12%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
MCE: FAE.MC

Faes Farma, S.A.

CEO Mr. Mariano Ucar Angulo
IPO Date Jan. 3, 2000
Location Spain
Headquarters Avenida Autonomía 10
Employees 1,748
Sector Health Care
Industries
Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

Similar companies

VIS.MC

Viscofan, S.A.

USD 61.42

0.44%

EBRO.MC

Ebro Foods, S.A.

USD 16.18

0.35%

VID.MC

Vidrala, S.A.

USD 91.52

-0.29%

ALM.MC

Almirall, S.A.

USD 8.60

3.71%

ENC.MC

ENCE Energía y Celulosa, S.A.

USD 3.25

1.25%

StockViz Staff

January 15, 2025

Any question? Send us an email